← FDA DRUG APPROVALS

FDA ANDA · ANDA209907

TADALAFIL

Sponsor: HETERO LABS LTD III

APPLICATION
ANDA209907
TYPE
ANDA
ORIGINAL APPROVAL
2019-02-05
LATEST ACTION
2023-04-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

TADALAFILPrescription
TADALAFIL 20MG · TABLET · ORAL

Approval history

2023-04-24Labeling · Supplement 5 · standardAP
2019-02-05UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →